Ken Griffin
BCAX

Ken Griffin’s Bicara Therapeutics BCAX Stock Holding History

Ken Griffin’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203K Buy
+10,200
New +$176K ﹤0.01% 11399

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Ken Griffin's BCAX Position: Q1 2026 in Review

Ken Griffin increased its Bicara Therapeutics (BCAX) stake by 115% in Q1 2026, buying an estimated $15.3M and bringing the position to 1,659,342 shares worth $33M. The position accounts for 0.01% of the portfolio, ranked #1759.

Ken Griffin first reported a position in BCAX in Q3 2024 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Ken Griffin held 1,659,342 shares of Bicara Therapeutics worth $33M as of Q1 2026.
  • Ken Griffin bought 887,084 Bicara Therapeutics shares in Q1 2026, an estimated $15.3M.
  • Bicara Therapeutics made up 0.01% of Ken Griffin's portfolio in Q1 2026, its #1759 holding.
  • Ken Griffin first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.